ANTG CONTINUES TO DELIVER ON QUALITY AND PURITY
We have successfully passed three consecutive TGO93 and TGO100 tests on our medicinal cannabis products since our first commercial harvest at the end of 2019.
Implemented by the Therapeutic Goods Administration (TGA), the TGO93 and TGO100 standards test for contaminants such as moulds, microbials and yeast. They ensure medicinal cannabis manufacturers provide the highest quality and reliability in therapeutics goods on the market. Failing TGO93 and TGO100 testing requires products to be destroyed or to undergo chemical or physical sterilisation.
At ANTG, our medicinal cannabis is cultivated naturally, primarily under the sun. We grow in an all natural, renewable medium and in a pesticide free environment. This, coupled with our assurance to quality control at every step of the cultivation and production process, helps us deliver the purest, highest quality medicinal cannabis products possible, eliminating the need to sterilise our cannabis products using gamma irradiation.
We’re thrilled to announce we have received our export licence from the Drug Control Section of the ODC (Office of Drug Control). We’re firmly on course to continue to lead the way and be the first medicinal cannabis company in Australia to export cannabis flower to the EU since export was legalised in 2018.
One of ANTG’s proprietary medicinal cannabis strains, EVE Cannabis Indica, has been listed on the Australian Register of Therapeutic Goods (ARTG). The ARTG is a reference of therapeutic goods that can lawfully be supplied in or exported from Australia.
In conjunction with the HMRI and lead biomedical scientist Dr Matt Dun, we’re investigating the anticancer properties of our plant varieties. Dr Matt Dun shares his initial thoughts on the joint research project.
We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.LEARN ABOUT ANTG HERE >